Compare PD & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PD | ABUS |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.5M | 884.7M |
| IPO Year | 2019 | 2008 |
| Metric | PD | ABUS |
|---|---|---|
| Price | $7.58 | $4.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $17.00 | $5.00 |
| AVG Volume (30 Days) | ★ 3.5M | 2.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.71 | 13.64 |
| EPS | ★ 1.73 | N/A |
| Revenue | ★ $467,499,000.00 | $6,171,000.00 |
| Revenue This Year | $8.16 | $125.30 |
| Revenue Next Year | $3.75 | N/A |
| P/E Ratio | $4.60 | ★ N/A |
| Revenue Growth | ★ 8.54 | N/A |
| 52 Week Low | $6.18 | $2.71 |
| 52 Week High | $19.70 | $5.10 |
| Indicator | PD | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 58.40 |
| Support Level | $6.18 | $4.18 |
| Resistance Level | $16.48 | $5.01 |
| Average True Range (ATR) | 0.37 | 0.22 |
| MACD | 0.29 | 0.03 |
| Stochastic Oscillator | 74.40 | 80.79 |
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.